Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q3

2342.TEDINET S100Q04J
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 35
MetricValuePeriodScopeSource row
Revenue¥8.5bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥12.6bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥153m2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥385m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥344m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥1.4bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥182m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥803m2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥171m2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥795m2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥10.9bnat 2022-12-31Cons.Assets
Total assets¥10.4bnat 2022-03-31Cons.Assets
Total assets¥10.2bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥4.2bnat 2022-12-31Cons.Liabilities
Total liabilities¥3.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-03-31Cons.Net assets
Net assets / equity¥5.6bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥4.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥10.812022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥7.542022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.572021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-10.552021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.462021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio60.4%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.7%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥4m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥157m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥132m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥6.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥1m
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥179m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥8.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥310m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥9m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥138m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥3.9bn
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥9m
jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥5.7bn
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥491,000
jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥203m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥9.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥9m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 368
ItemContextValueUnit
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member141400
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0083
Number of shares held in own name treasury shares etcCurrentQuarterInstant141400
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant141400
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0083
Cash and depositsPrior1YearInstant4618521000JPY
Cash and depositsCurrentQuarterInstant3437715000JPY
Notes and accounts receivable trade and contract assetsPrior1YearInstant894115000JPY
Notes and accounts receivable trade and contract assetsCurrentQuarterInstant1004658000JPY
Short term investment securitiesPrior1YearInstant5955000JPY
Short term investment securitiesCurrentQuarterInstant－JPY
Merchandise and finished goodsPrior1YearInstant1024229000JPY
Merchandise and finished goodsCurrentQuarterInstant1525365000JPY
Work in processPrior1YearInstant638811000JPY
Work in processCurrentQuarterInstant721374000JPY
Raw materials and suppliesPrior1YearInstant51862000JPY
Raw materials and suppliesCurrentQuarterInstant170567000JPY
Other caPrior1YearInstant477639000JPY
Other caCurrentQuarterInstant719033000JPY
Allowance for doubtful accounts caPrior1YearInstant-1294000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-912000JPY
Current assetsPrior1YearInstant7709841000JPY
Current assetsCurrentQuarterInstant7577803000JPY
Buildings and structures netPrior1YearInstant1069435000JPY
Buildings and structures netCurrentQuarterInstant1109936000JPY
LandPrior1YearInstant812230000JPY
LandCurrentQuarterInstant905846000JPY
Other net ppePrior1YearInstant111002000JPY
Other net ppeCurrentQuarterInstant168768000JPY
Property plant and equipmentPrior1YearInstant1992668000JPY
Property plant and equipmentCurrentQuarterInstant2184551000JPY
GoodwillPrior1YearInstant365266000JPY
GoodwillCurrentQuarterInstant606865000JPY
Other iaPrior1YearInstant12487000JPY
Other iaCurrentQuarterInstant12560000JPY
Intangible assetsPrior1YearInstant377754000JPY
Intangible assetsCurrentQuarterInstant619426000JPY
Investment securitiesPrior1YearInstant109791000JPY
Investment securitiesCurrentQuarterInstant162192000JPY
Other ioaPrior1YearInstant274377000JPY
Other ioaCurrentQuarterInstant410353000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-23722000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-23722000JPY
Investments and other assetsPrior1YearInstant360445000JPY
Investments and other assetsCurrentQuarterInstant548822000JPY
Noncurrent assetsPrior1YearInstant2730868000JPY
Noncurrent assetsCurrentQuarterInstant3352800000JPY
AssetsPrior1YearInstant10440710000JPY
AssetsCurrentQuarterInstant10930603000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass